Literature DB >> 17885461

Long-acting contraceptives in adolescents.

Lama L Tolaymat1, Andrew M Kaunitz.   

Abstract

PURPOSE OF REVIEW: To help clinicians guide adolescent patients to sound choices regarding long-acting contraceptives. The safety, side effects and non-contraceptive benefits of injectable, implantable and intrauterine contraception are detailed. RECENT
FINDINGS: The use of depot medroxyprogesterone acetate contraceptive injections has been associated with declines in teenage pregnancies in the United States. Although the US Food and Drug Administration has placed a black box warning concerning skeletal health and depot medroxyprogesterone acetate, data in adolescents confirm that declines in bone mineral density with depot medroxyprogesterone acetate are fully reversible. Concerns regarding skeletal health should not restrict the initiation or continuation of depot medroxyprogesterone acetate in adolescents. A highly effective, convenient, and easy to insert/remove single rod progestin-only contraceptive implant (Implanon) is now available in the United States. Although not widely used in adolescents, intrauterine devices offer selected adolescents convenient, highly effective, safe birth control. Use of the progestin-releasing intrauterine device (Mirena) is also associated with important non-contraceptive benefits.
SUMMARY: The efficacy and convenience associated with long-acting contraceptives make them indispensable for adolescent patients. This review will help clinicians guide teenage patients towards sound contraceptive choices and the successful long-term use of injectable, implantable and intrauterine methods of birth control.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885461     DOI: 10.1097/GCO.0b013e3282ef1cd2

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  3 in total

Review 1.  Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.

Authors:  Robert C Bollinger; Chloe L Thio; Mark S Sulkowski; Jane McKenzie-White; David L Thomas; Charles Flexner
Journal:  Lancet HIV       Date:  2019-12-20       Impact factor: 12.767

Review 2.  Update on hormonal contraception and bone density.

Authors:  Michelle M Isley; Andrew M Kaunitz
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

3.  Depot medroxyprogesterone acetate use is not associated with risk of incident sexually transmitted infections among adolescent women.

Authors:  Amy Romer; Marcia L Shew; Susan Ofner; Melissa L Gilliam; Summer L Martins; J Dennis Fortenberry
Journal:  J Adolesc Health       Date:  2012-06-05       Impact factor: 5.012

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.